BOTHELL, Wash. & SAN DIEGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today presented data on SGN-70, a monoclonal antibody targeting CD70, demonstrating its potential for the treatment of autoimmune diseases at the American Association of Immunologists (AAI) annual meeting being held in San Diego, California. In addition, Seattle Genetics’ anti-CD70 therapies were featured during the conference in an AAI Major Symposium entitled “TNF Family Members in Inflammation, Autoimmunity and Cancer.”
